Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 90 clinical trials
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

This phase I/Ib trial seeks to find out the best dose, possible benefits and/or side effects of cabozantinib in combination with enfortumab vedotin in treating urothelial cancer that has spread

  • 0 views
  • 04 Oct, 2022
  • 1 location
Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)

This is an open label, non-randomized phase 2 study of the combination of pembrolizumab and cabozantinib to assess overall response rate (ORR), progression free survival at 6 months (PFS6), and

carcinoma
advanced urothelial carcinoma
transitional cell carcinoma
measurable disease
pembrolizumab
  • 22 views
  • 01 Jul, 2022
  • 2 locations
Phase II Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma

This is a multi-site, single arm phase II trial of cabozantinib for IMDC all-risk frontline metastatic renal cell carcinoma (mRCC) patients OR any line mRCC patients who have not previously been

  • 0 views
  • 10 Mar, 2022
  • 1 location
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that have spread to other places in

vegf
brain metastases
gonadotropin
programmed cell death 1 ligand 1
major surgery
  • 351 views
  • 27 Oct, 2022
  • 171 locations
Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection

This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that has spread to other places in the body (advanced) and who are undergoing

hepatitis
HIV Vaccine
antiretroviral
enzyme-linked immunosorbent assay
antiretroviral therapy
  • 0 views
  • 24 Oct, 2022
  • 1 location
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA)

cabozantinib will have synergistic effect when combined with checkpoint-based immunotherapeutics like durvalumab in this patient population. This is a phase I/II, open label, multi-cohort trial looking at

systemic therapy
epidermal growth factor receptor
durvalumab
measurable disease
esophageal adenocarcinoma
  • 67 views
  • 30 May, 2022
  • 1 location
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer

This phase I trial evaluates the effects of CBM588 in combination with standard therapies, nivolumab and cabozantinib, in treating patients with kidney cancer that has spread to other places in

  • 0 views
  • 01 Dec, 2021
  • 1 location
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma

This phase II trial studies how well cabozantinib and temozolomide work in treating patients with leiomyosarcoma or other soft tissue sarcoma that cannot be removed by surgery (unresectable) or

  • 0 views
  • 04 Oct, 2022
  • 5 locations
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study (CABATEN)

CABATEN is a multicohort phase II study of cabozantinib plus atezolizumab in advanced and progressive tumors from endocrine system. The primary objective is to assess the efficacy of

neuroendocrine tumor
paraganglioma
basic fibroblast growth factor
carcinoid tumor
chemotherapy regimen
  • 0 views
  • 24 Mar, 2022
  • 14 locations
Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study (CABOMAYOR)

absence of data and concerns about possible secondary effects associated, can preclude clinicians to treat aged fragile patients with cabozantinib. A pilot phase II trial would help to have data on safety

  • 6 views
  • 22 Mar, 2022
  • 11 locations